Tumor suppressor p53 plays an important role in cancer prevention. Under normal conditions, p53 is maintained at a low level. However, in response to various cellular stresses, p53 is stabilized and activated, which, in turn, initiates DNA repair, cellcycle arrest, senescence and apoptosis. Post-translational modifications of p53 including phosphorylation, ubiquitination, and acetylation at multiple sites are important to regulate its activation and subsequent transcriptional gene expression. Particularly, phosphorylation of p53 plays a critical role in modulating its activation to induce apoptosis in cancer cells. In this context, previous studies show that several serine/threonine kinases regulate p53 phosphorylation and downstream gene expression. The molecular basis by which p53 and its kinases induce apoptosis for cancer prevention has been extensively studied. However, the relationship between p53 phosphorylation and its kinases and how the activity of kinases is controlled are still largely unclear; hence, they need to be investigated. In this review, we discuss various roles for p53 phosphorylation and its responsible kinases to induce apoptosis and a new therapeutic approach in a broad range of cancers.
and activated to induce apoptosis-related genes. To date, 10 kinases have been identified to phosphorylate p53 for apoptosis at specific serine/threonine residues in the N-and C-terminus domains. Nine phosphorylation sites (serine 20, 33, 46, 366 , and 392 and threonine 81, 304, 377, and 387) for apoptosis have been detected in different types of cancer cell lines (Table 1) . [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Intriguingly, a kinase phosphorylates several sites on p53, whereas several kinases phosphorylate the same site. In particular, a growing number of studies have indicated that Ser46 phosphorylation is mainly involved in the regulation of apoptosis after DNA damage. A thorough understanding of how p53 is phosphorylated by kinases to induce apoptosis will be extremely useful in the development of new strategies for preventing cancer.
| N-terminal phosphorylation sites
Polo-like kinase 3 (Plk3) and checkpoint kinase 2 (Chk2) phosphorylated p53 at Ser20 to induce its transcriptional activity in MDAPanc-28 and HCT116 cells. 3, 4 Overexpression of WT Plk3 in HCT116 p53 +/+ cells induced rapid apoptosis, whereas overexpression of WT Plk3 in HCT116 p53 −/− cells induced delayed onset of apoptosis.
Additionally, several studies have shown that Plk3 is associated with cell cycle arrest and apoptosis by the p53 pathway by interacting directly with p53 and phosphorylating p53 on Ser20 in response to DNA damage. 13, 14 Therefore, Plk3 plays a pivotal role not only in the regulation of microtubule dynamics and centrosomal function but also in cell cycle arrest and apoptosis. 15 Bax activation, which leads to cytochrome c release followed by caspase activation and apoptosis. 4 Ser33 as well as Ser46 were phosphorylated by p38 in response to UV radiation in A549 cells. 
| C-terminal phosphorylation sites
Thr304 and 377 were phosphorylated by leucine-rich repeat kinase F I G U R E 3 Proposed model for dualspecificity tyrosine-phosphorylationregulated kinase 2 (DYRK2)-mediated p53 phosphorylation and apoptosis in response to DNA damage. In the unstressed condition, DYRK2 is ubiquitinated by MDM2 and SIAH2 to elicit its constitutive degradation. p53 is also ubiquitinated by MDM2 and maintained at a low level. In response to various genotoxic stresses, p53 is stabilized and activated by phosphorylation at Ser15 and Ser20. Cytoplasmic DYRK2 is activated and targeted to the nucleus and is phosphorylated by ataxia telangiectasia mutated (ATM). DYRK2 then phosphorylates p53 at Ser46. Ser46 phosphorylation triggers the induction of apoptosis-related genes, as shown in Figure 1 phosphorylation of p53 at Ser46 by DYRK2 regulates apoptotic cell death in response to DNA damage. 1, 19 Previous findings also showed that p53 was phosphorylated by
PKCδ in MCF7 and U2OS cells upon exposure to genotoxic agents ( Figure 4) . 7 PKCδ-mediated phosphorylation was required for the interaction of PKCδ with p53. PKCδ also induced the promoter activity of p53 through the p53 core promoter element and that the induction was enhanced following DNA damage. 20 Nuclear import of PKCδ was required for initiation of the apoptotic pathway. 21 In this context, PKCδ also induces apoptosis through various nuclear substrates, such as DNA-dependent protein kinase, 22 phospholipid scramblase 3, 23 lamin B, 24 Rad9, 25 or Evi-1 and PLZF. 26 Intriguingly, our recent report demonstrated that PKCδ was transcriptionally regulated by p53 upon genotoxic stress. This regulation was tightly controlled in a positive feedback mechanism to induce apoptosis. 27, 28 Taken together, uncovering the relationship between Ser46 phosphorylation and the crosstalk with its kinases provides a novel insight into apoptosis signaling for cancer treatment and prevention. 29 Further studies are required for a better understanding of the molecular basis of Ser46 phosphorylation of p53 to induce apoptosis.
| p5 3 PHOSPHORYLATION IN TUMOR SUPPRESSIVE ROLES
Does p53 phosphorylation contribute to any tumor suppressive role?
Several studies have shown that p53 phosphorylation (eg, Ser15, 20, 37, 46) induces apoptosis through multiple effectors, such as inositol pyrophosphates, selenocysteine, nutlin-3a, and palmdelphin in cancer cells. [30] [31] [32] [33] Moreover, there has been considerable effort to understand the mechanism of p53 regulation by post-translational modification using genetically engineered mouse models. 34 A previous report showed partially impaired p53-dependent apoptosis in thymocytes from mice defective for p53 phosphorylation at Ser46 (S46A mutant) whereas its tumorigenic phonotype was not confirmed. 35 Other reports also showed that mice defective for p53 phosphorylation at several sites (S312A and S18/23A mutants) were more susceptible to tumorigenesis, although mice engineered to have p53 gene knockout developed tumors at an increased rate. [36] [37] [38] In this way, p53 phosphorylation is important for p53-dependent suppression of tumorigenesis in mice.
In contrast, the p53 gene is one of the most common sites for genetic alterations, leading to the expression of mutant p53 proteins, in human solid cancers as it is mutated in more than 50% of cancer cases worldwide. 39 Additionally, inherited p53 gene mutation in patients with Li-Fraumeni syndrome carrying an R248Q mutation is also characterized by a strikingly increased risk of early-onset cancers including breast carcinomas, brain tumors, leukemias and sarcomas, among others. 40 Some mutant p53 proteins give rise to a more aggressive tumor profile, suggesting they have acquired gain-of-function activity. 41 Accordingly, does mutant p53 phosphorylation contribute to tumor progression or not? For example, mutant p53 protein in UV-induced murine primary skin tumors and cultured cell lines was constitutively phosphorylated at Ser15 residue and localized in the nuclei. 42 Conversely, Ser392 phosphorylation of mutant p53 could not confer cellular resistance to DNA-damaging agents. 43 Analysis of mutant p53 phosphorylation by phosphoantibodies showed a marked increase in the degree of p53 phosphorylation in tumor-derived cell lines as well as in freshly processed tumor tissues. 44 Therefore, phosphorylation of mutant p53 would be important for tumor progression, despite a small number of studies with conflicting findings. 45 It is not surprising that kinases involved in p53 phosphorylationinducible apoptosis are maintained at low level or mutated in cancer cells. For instance, recent reports showed that the expression of DYRK2 protein was reduced in cancer tissues compared with that in normal tissues and was correlated with patient survival in many types of cancer. [46] [47] [48] [49] [50] Recent genome-wide association studies also identified that somatic mutation of the DYRK2 gene was correlated with breast cancer risk. 51 Moreover, DYRK2 was ubiquitinated by MDM2 and SIAH2, resulting in its constitutive degradation and impaired DYRK2-mediated phosphorylation of p53 at Ser46. 52, 53 In response to genotoxic stress, DYRK2 was phosphorylated at Thr33
and Ser369 by ATM, stabilized by inhibiting MDM2-mediated degradation, to induce the kinase activity toward p53 at Ser46 in the nucleus. 52 Moreover, knockdown of DYRK2 increased cell proliferation in MCF7 cells and tumor progression in vivo through the escape of c-Jun and c-Myc from ubiquitination-mediated degradation. 54, 55 These findings collectively indicate that DYRK2 is implicated in an antitumor effect. Further studies are required for cancer prevention to define how the activity and expression level of DYRK2 is controlled in each type of cancer.
PKCδ gene is most commonly mutated in gastrointestinal cancers (pancreatic, stomach, and colorectal), with a lesser mutation burden in melanomas and lung cancers. 56 However, PKCδ shows conflicting evidence as to whether it acts as an oncogene or as a tumor suppressor. PKCδ appeared to be a tumor suppressor because of its proapoptotic functions. 57 Inhibiting PKCδ blocked both basal transcription of the human p53 gene and initiation of transcription from the human p53 promoter. 58 It is thus conceivable that the tumorsuppressing effects of PKCδ are mediated at least in part through activating p53 transcription. Knockdown of PKCδ in colon cancer cells increased tumor growth, and overexpression of PKCδ in keratinocytes decreased tumorigenicity in immunodeficient mice. 59, 60 Decreased PKCδ levels correlated with increased tumor grade in bladder and endometrial cancer and glioma. [61] [62] [63] In contrast, PKCδ promoted tumor progression of lung and pancreatic cancers in certain contexts. 64, 65 Additional evidence is definitely required to determine each cancer-specific PKCδ function.
HIPK2 is activated by numerous genotoxic agents and can be deregulated in tumors by several conditions including hypoxia.
66
HIPK2 was required for the Fbw7-dependent proteasomal degradation of Notch1 by phosphorylating its intracellular domain, suggesting that HIPK2 regulates tumor progression. 67 Additionally, vimentin downregulation by HIPK2 correlated with inhibition of breast tumor cell invasion. 68 In heterozygous p53-deficient background, mice with heterozygous loss of HIPK2 gene developed more lymphomas after irradiation than those with wild-type HIPK2 gene. 69 These findings indicate that HIPK2 is a promising target for cancer treatment.
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| CON CLUDING REMARKS
The ability of p53 phosphorylation to induce apoptosis has significant antitumor potential that can be exploited for cancer treatment. p53
phosphorylation is a complex process that associates with various proteins and multiple layers of regulation. The molecular basis of how p53 and its kinases induce apoptosis for cancer prevention has been extensively studied. However, the relative contribution of each regulator and how stability and activity of kinases are controlled remains to be determined. induced a rapid nuclear translocation of PKCδ and PKCδ-dependent phosphorylation of caspase-3 in myeloid leukemia cell lines and primary acute myeloid leukemia cells, suggesting that PEP005 has potent antileukemic activity. 71 Roy-Bz potently inhibited the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway with caspase-3 activation. It also exerted a PKCδ-dependent antitumor effect in xenograft mouse models. 72 Consistently, reactivation of WT p53 and downregulation and/or restoration of mutant p53 may also be beneficial in many tumors.
In fact, p53 restoration resulted in elevated apoptosis and decreased tumor growth in mice inheriting a p53 null or R172H mutation. 73, 74 Moreover, a mutant-p53-targeting compound, PRIMA-1MET (APR-246), could restore mutant p53 proteins to a WT p53 conformation and lead to enhanced expression of Puma, Noxa and Bax in p53 mutant cells. In 2012, APR-246 was tested in phase I/IIa clinical trials. 75 Finally, once we understand the detailed mechanisms of p53 phosphorylation and its kinases for apoptosis, we will be able to develop highly effective and specific strategies for cancer prevention.
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